US Patent Issued to Regeneron Pharmaceuticals on April 29 for "Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation" (New York Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,286,677, issued on April 29, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation" was invented by Yurong Xin (Tarrytown, N.Y.), Jesper Gromada (Tarrytown, N.Y.), Xiping Cheng (Tarrytown, N.Y.), Frederick Dewey (Tarrytown, N.Y.), Tanya Teslovich Dostal (Tarrytown, N.Y.), Claudia Schurmann (Tarrytown, N.Y.), Aris Baras (Tarrytown, N.Y.) and Noura Abul-Husn (Tarrytown, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides methods of identifying a human subject as a candidate for treating or inhibiting a liver diseas...